Noramco, a Wilmington, Delaware-headquartered producer of specialty active pharmaceutical ingredients (APIs), and SPI Pharma, a Wilmington, Delaware-headquartered manufacturer and supplier of functional excipient platforms and the development and licensing of dosage forms, have agreed to develop and license a set of “value-added” formulation packages for global pharmaceutical manufacturers of finished dosage forms.

The agreement will focus on finished-dosage products for licensing through dossiers developed by SPI Pharma for implementation by generic and branded pharmaceutical companies. Neither Noramco nor SPI intend to produce or market finished-dosage forms, according to the companies.

Under the agreement, Noramco and SPI Pharma will demonstrate proof-of-concept of a select set of finished drug products in patient-friendly dosage forms, which will be out-licensed for scale-up, registration, and marketing. Customers can also choose upfront to customize formulation packages for specific APIs on a milestone-based, pay-for-success business model.

Source: Noramco and SPI Pharma